Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Trial Finds Oral Drug Could Become Standard of Care for In Vitro Fertilization

XTALKS VITALS NEWS

IVF

IVF is just one of the many available methods used to assist women with reproductive issues.

Share this!

March 9, 2017 | by Sarah Hand, M.Sc.

Global healthcare and research company, Abbott, has announced the results of their phase III clinical trial assessing the efficacy of oral dydrogesterone in women undergoing in vitro fertilization (IVF). The Lotus I study involved over 1,000 women across 38 international study sites, and found that the drug had similar efficacy and tolerability compared to the standard of care, micronized vaginal progesterone (MVP).

IVF is just one of the many available methods used to assist women with reproductive issues. Dydrogesterone, a progesterone analogue, is used to prepare the uterine lining for implantation of a fertilized egg.

While MVP remains the most common form of the hormone administered in IVF clinics, it can cause unpleasant side effects, including irritation and discharge. Based on the results of the Lotus I clinical trial, oral dydrogesterone could be a viable treatment alternative to MVP.



“The findings from this study have the potential to have important implications for women undergoing IVF,” said Dr. Herman Tournaye, Director of the Center for Reproductive Medicine at Universitair Ziekenhuis Brussel, and lead clinical researcher for the Lotus I study. “We found oral dydrogesterone to be effective, well tolerated and easy to administer – all of which point to it becoming the new preferred treatment option.”

Compared to patients given MVP, those that were randomized to receive oral dydrogesterone showed similar evidence of ongoing pregnancy at 12 weeks gestation. This endpoint was assessed by testing for the presence of a fetal heartbeat.

Pregnancy rates at 12 weeks gestation were 37.6 percent for the oral dydrogesterone treatment group, and 33.1 percent for patients who received MVP. Full findings – including those pertaining to live birth rates – were published in the journal, Human Reproduction.

Currently, oral dydrogesterone manufactured by Abbott is only available in countries outside the US. The drug is currently approved for a number of region-specific indications, including recurrent miscarriage, endometriosis and hormone replacement therapy (HRT).


Keywords: Clinical Trials, IVF, Reproductive Technology


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New Approach Could Allow Red Blood Cells to be Manufactured

March 27, 2017 - UK researchers at the University of Bristol have developed an immortal line of early adult erythroblasts capable of continuously producing mature red blood cells.

Featured In: Biotech News


Lung Cancer Recurrence Could Be Better Detected Using Biomarker Blood Test

March 24, 2017 - The results of a recent prospective clinical trial found that a biomarker blood test could detect lung cancer recurrence a full six months before imaging methods could spot the disease.

Featured In: Biotech News


Use of Testosterone Treatments Boosted by DTC Ad Campaigns

March 24, 2017 - Those with a stake in the pharmaceutical industry often question the effectiveness of direct-to-consumer (DTC) advertising, and whether it truly influences consumers to talk to their doctors about medical conditions and perhaps even ask for drugs by name.

Featured In: Pharmaceutical Marketing News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.